Generic Name: doravirine + tenofovir disoproxil fumarate + lamivudine

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Single-Tablet Regimens

Company: Merck & Company

Approval Status: Experimental

Generic Version Available: No

Experimental Code: MK-1439A


Drug Recommendation

MK-1439A has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.


General Info

MK-1439A is an experimental HIV medication. It contains three different types of HIV drugs: one non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs). It is currently in Phase III clinical trials.

MK-1439A is a single-tablet regimen containing generic versions of two currently approved HIV medications (tenofovir disoproxil fumarate and lamivudine) and one experimental HIV medication (doravirine).


Dosage

Adult Dose: One tablet once a day. Each tablet contains 100mg doravirine + 300mg tenofovir disoproxil fumarate + 300mg lamivudine.

Pediatric Dose: N/A

Dosing Info: This is a complete one-pill, once-daily drug regimen.


Side Effects

N/A


Drug Interactions

N/A


Other Info

N/A


Last Revised: January 24, 2016